Supernus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Supernus Pharmaceuticals has a total shareholder equity of $921.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.3B and $356.2M respectively. Supernus Pharmaceuticals's EBIT is $13.4M making its interest coverage ratio -1.7. It has cash and short-term investments of $254.9M.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | -1.7x |
Cash | US$254.87m |
Equity | US$921.52m |
Total liabilities | US$356.16m |
Total assets | US$1.28b |
Recent financial health updates
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well
Oct 19Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?
Oct 19Supernus Pharmaceuticals (NASDAQ:SUPN) Seems To Use Debt Rather Sparingly
Jul 05Recent updates
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
Apr 24Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Mar 04We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well
Oct 19Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment
Oct 10Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio
Aug 19Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear
Aug 16Supernus: A Work In Progress
Jul 29Supernus: New Beginnings
Mar 28Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts
Dec 02Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?
Nov 30Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?
Oct 19Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?
Aug 31Supernus: Well Prepared For Upcoming Challenges
Aug 26Supernus Pharmaceuticals (NASDAQ:SUPN) Seems To Use Debt Rather Sparingly
Jul 05Financial Position Analysis
Short Term Liabilities: SUPN's short term assets ($493.1M) exceed its short term liabilities ($290.2M).
Long Term Liabilities: SUPN's short term assets ($493.1M) exceed its long term liabilities ($66.0M).
Debt to Equity History and Analysis
Debt Level: SUPN is debt free.
Reducing Debt: SUPN has no debt compared to 5 years ago when its debt to equity ratio was 78.2%.
Debt Coverage: SUPN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SUPN has no debt, therefore coverage of interest payments is not a concern.